Financial Ratios

FRESENIUS KABI ONCOLOGY LTD.

NSE : NABSE : 532545ISIN CODE : INE575G01010Industry : Pharmaceuticals & DrugsHouse : Fresenius Kabi Oncology - MNC
BSE132.450 (0 %)
PREV CLOSE ( ) 132.45
OPEN PRICE ( ) 132.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 132.45 (20430)
VOLUME 91518
TODAY'S LOW / HIGH ( )132.00 132.60
52 WK LOW / HIGH ( ) 132132.6
NSE
This Company is not listed in NSE
Select year
ParticularsMar2019Mar2018Mar2017Mar2016Mar2015
Operational & Financial Ratios
   Earnings Per Share (Rs)-3.171.15-0.14-4.85-9.23
   CEPS(Rs)0.044.372.72-1.79-6.63
   DPS(Rs)0.000.000.000.000.00
   Book NAV/Share(Rs)23.9026.9125.7525.8830.67
   Tax Rate(%)12.08-6.29212.3716.51-1.86
Margin Ratios
   Core EBITDA Margin(%)13.7118.5613.29-2.13-19.75
   EBIT Margin(%)-3.729.106.11-12.60-26.76
   Pre Tax Margin(%)-9.302.610.34-17.88-31.82
   PAT Margin (%)-8.182.77-0.38-14.93-32.41
   Cash Profit Margin (%)0.1110.547.29-5.51-23.27
Performance Ratios
   ROA(%)-3.971.45-0.19-6.82-12.72
   ROE(%)-12.474.37-0.55-17.16-28.99
   ROCE(%)-2.726.804.26-8.05-14.87
   Asset Turnover(x)0.490.520.500.460.39
   Sales/Fixed Asset(x)0.991.141.090.890.77
   Working Capital/Sales(x)2.842.482.676.995.96
Efficiency Ratios
   Fixed Capital/Sales(x)1.010.880.921.121.30
   Receivable days86.1778.8079.3982.8886.38
   Inventory Days212.57202.03225.41238.93250.26
   Payable days261.77216.69249.49274.27293.13
Valuation Parameters
   PER(x)0.000.000.000.000.00
   PCE(x)0.000.000.000.000.00
   Price/Book(x)0.000.000.000.000.00
   Yield(%)
   EV/Net Sales(x)0.720.700.850.800.79
   EV/Core EBITDA(x)3.613.085.51446.42-8.47
   EV/EBIT(x)-19.487.6213.66-6.25-2.82
   EV/CE(x)0.350.360.390.370.29
   M Cap / Sales0.000.000.000.000.00
Growth Ratio
   Net Sales Growth(%)-6.2412.7315.2316.6813.71
   Core EBITDA Growth(%)-16.9165.839734.12102.2635.86
   EBIT Growth(%)-138.1765.76155.6146.23-17.20
   PAT Growth(%)-375.34910.6697.0847.42-41.10
   EPS Growth(%)-375.34910.6697.0847.42-31.13
Financial Stability Ratios
   Total Debt/Equity(x)1.141.041.190.960.67
   Current Ratio(x)1.461.631.521.151.14
   Quick Ratio(x)0.700.790.650.420.57
   Interest Cover(x)-0.671.401.06-2.39-5.28
   Total Debt/Mcap(x)

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.